Ultragenyx is trading at $17.55, up 5.50% amid a biotech rally; the specific intraday catalyst is unclear.
- XBI rose 2.13% in regular trading; broader-market gains supported a risk-on backdrop.
- Ultragenyx reported third-quarter revenue of $173 million, reaffirmed 2026 revenue guidance, and announced workforce cuts and program terminations; early coverage noted a negative premarket reaction.
- UK regulators granted conditional marketing authorisation for Dojolvi on October 30; coverage does not link it to the November 4 rise.